Download Provectus Pharmaceuticals Issues Letter to Shareholders Tuesday

Provectus Pharmaceuticals Issues Letter to
Shareholders
Tuesday October 5, 2004
KNOXVILLE, Tenn., October 5, 2004 /PRNewswire-FirstCall/ -- Provectus Pharmaceuticals, Inc.
(OTCBB: PVCT - News) -- Craig Dees Ph.D., CEO of Provectus Pharmaceuticals, sent the following letter,
dated Oct. 5, to the shareholders of Provectus Pharmaceuticals:
Dear Shareholder:
I am pleased to be writing this letter to you on behalf of the entire team at Provectus Pharmaceuticals, Inc. Our
excitement continues to grow based on our recent advancements. We are making continuing progress in the
areas of oncology, dermatology, and sale of over-the-counter (OTC) products.
We have just completed a major milestone by submitting the Investigational New Drug (IND) application for
our cancer drug, PV-10. Pending FDA review of our IND, we anticipate beginning clinical trials in 2005.
As many of you know, PV-10 is an exciting prospect on the cancer battlefront that, based on pre-clinical
trials, is delivered precisely to tumors with minimal risk of harm to surrounding healthy tissue or systemic
side effects. We believe PV-10 will help in the treatment of some of the most dangerous, hard-to-treat solid
tumors of the breast, prostate and liver. Our pre-clinical trials have been highly successful and lead us to
believe that this new drug may have widespread impact in the war on cancer.
Our primary goal at Provectus continues to be the development of advanced treatments that are safer, more
effective, less invasive and more economical than conventional therapies. Our second drug, PH-10, is used in
the dermatology field, primarily on psoriasis. Whereas PV-10 is injected, PH-10 is a topical treatment. Both
are based on the same targeting mechanism designed to treat abnormal cells while sparing healthy cells. Phase
One clinical trials with PH-10 already have been completed, and we anticipate that Phase Two clinical trials
on psoriasis will begin soon.
In addition to our ethical pharmaceutical development efforts, our subsidiary, Pure-ific Corp., is making
excellent progress. Pure-ific Corp. develops and sells OTC pharmaceutical products, and is designed to bring
immediate revenue into the company to support the work of the other divisions and reduce our reliance on
outside funding.
Our most advanced OTC product, Pure-ific Anti-bacterial Hand Spray, is effective and convenient -- killing
over 99.9 percent of germs and improving upon conventional messy gel products. With new infectious
diseases becoming increasingly common, concern is at an all-time high among our target customers, including
mothers with young children, travelers, and the elderly. Currently, we have an agreement with
AmerisourceBergen to begin selling this product in independent pharmacies; we are finalizing arrangements
to sell this product in at least one major retail chain; and we are negotiating with several other retail chains.
Meanwhile, our Website www.pureific.com allows consumers to purchase the product online. In addition,
coming right behind the anti-bacterial hand spray are Pure-ific Corp.'s products for disposable glove users and
a novel product for acne sufferers.
1/2
To put all of this into perspective, we believe that Provectus is an emerging player in the huge and growing
pharmaceutical industry. We believe in our potential to improve health care worldwide, using technologies
and products that are innovative, yet easy to manufacture and license, and economical to use. Moreover, we
believe our products can significantly improve existing treatments for cancer and other serious diseases.
Network 1 Financial Securities, Inc. has been retained by the Company as an investment banking and stock
advisory consultant. If you have any questions relative to investment issues, contact Damon Testaverde at
1.800.205.8031.
We appreciate your continued interest and involvement in our company. We are excited both about our
progress to date and the path ahead. The work being done at Provectus today will make a difference in
people's lives tomorrow. We are pleased to include you, as a Provectus shareholder, in this challenging and
exciting process.
I welcome your comments and questions.
Craig Dees Ph.D., CEO
Provectus Pharmaceuticals
For further information, please contact: Craig Dees, Ph.D., CEO of Provectus Pharmaceuticals,
+1-865-769-4011.
2/2